Is Sabra Health Care REIT (SBRA) Still Attractive After Strong Multi‑Year Share Price Gains

• If you are wondering whether Sabra Health Care REIT is still reasonably priced at around US$20.62, you are not alone. The stock's recent performance has put valuation front and center.
• The share price shows returns of 1.0% over 7 days, 5.2% over 30 days, 7.7% year to date, 27.1% over 1 year and 73.5% over 5 years, which naturally raises questions about what is already baked into the price.
• Recent coverage has focused on Sabra as a healthcare focused REIT, with investors paying close attention to its position in senior housing and skilled nursing facilities, as these areas are often linked to long term demographic demand. This context helps frame how the market may be thinking about risk and stability when assigning a value to the shares.
• On our valuation checks, Sabra scores 4 out of 6 for being undervalued, and next we will walk through the standard valuation approaches investors often use while also pointing to an even more holistic way to think about value at the end of the article.

Find out why Sabra Health Care REIT's 27.1% return over the last year is lagging behind its peers.

Approach 1: Sabra Health Care REIT Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future adjusted funds from operations and then discounts those cash flows back to today’s dollars to estimate what the business might be worth now.

For Sabra Health Care REIT, the model uses a 2 stage Free Cash Flow to Equity approach based on adjusted funds from operations. The latest twelve month free cash flow is about $361.6 million. Analyst estimates and extrapolations used by Simply Wall St project free cash flow reaching about $616.4 million in 2030, with interim years such as 2026 and 2027 in the $400 million range based on the provided projections.

By discounting this stream of projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of about $54.10 per share. Compared with the recent share price of around $20.62, this implies an intrinsic discount of roughly 61.9%, indicating that the shares are trading well below this model’s estimate of value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Sabra Health Care REIT is undervalued by 61.9%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Sabra Health Care REIT.

Approach 2: Sabra Health Care REIT Price vs Earnings

For profitable companies, the P/E ratio is a useful way to think about what you are paying for each dollar of earnings. It links directly to the business today, rather than long range projections, which is why many investors use it as a quick valuation cross check.

What counts as a fair P/E usually reflects two things: how the market views a company’s growth potential and how much risk investors see in those earnings. Higher expected growth and lower perceived risk often go hand in hand with a higher P/E, while slower growth or higher uncertainty tend to line up with a lower multiple.

Sabra Health Care REIT currently trades on a P/E of about 33.4x, compared with an average of roughly 25.7x for the Health Care REITs industry and around 85.7x for its peer group. Simply Wall St’s Fair Ratio for Sabra is 38.0x, which is its proprietary estimate of an appropriate P/E once earnings growth, industry, profit margins, market cap and risk profile are all taken into account.

Because the Fair Ratio blends these company specific factors, it often offers a more tailored reference point than broad industry or peer averages. Here, Sabra’s current 33.4x P/E sits below the 38.0x Fair Ratio, which points to the shares trading at a discount on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Sabra Health Care REIT Narrative

Earlier we mentioned that there is an even better way to think about valuation. On Simply Wall St you can use Narratives on the Community page to link your view of Sabra Health Care REIT’s story to a set of forecast assumptions, turn those forecasts into a Fair Value, and compare that Fair Value with the current price to decide whether the stock looks attractive or not. You can then see that view update automatically when new earnings, guidance or news arrives. Some investors might build a more optimistic Sabra Narrative around factors like senior housing demand, acquisitions and analyst targets in the US$21 to US$24 range. Others might set up a more cautious Narrative that leans on the consensus Fair Value of about US$21.69 and the 2026 funds from operations guidance to reflect higher execution and regulatory risks.

Do you think there's more to the story for Sabra Health Care REIT? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com